<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Patients with Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> in chemotherapy-induced remission received through dermal scarifications one or two doses per week of approximately 3 X 10(8) living BCG organisms (Pasteur Institute vaccine) </plain></SENT>
<SENT sid="1" pm="."><plain>This treatment was always followed by usually rapid increases by 1--4 log2 steps in the antibody titers to Epstein-Barr virus (EBV)-associated cell membrane antigens </plain></SENT>
<SENT sid="2" pm="."><plain>Titer increases of less than 2.5 log2 steps within the first month after the start of BCG treatment correlated with a significantly elevated frequency of extradural relapse as compared to that seen in patients with larger titer rises </plain></SENT>
<SENT sid="3" pm="."><plain>During this time, antibodies to EBV-associated <z:mp ids='MP_0001799'>viral</z:mp> capsid antigens and early antigens of D and R specificity, as well as antibodies against <z:e sem="disease" ids="C0019348" disease_type="Disease or Syndrome" abbrv="">herpes simplex</z:e>, varicella, cytomegalovirus, <z:e sem="disease" ids="C0025007" disease_type="Disease or Syndrome" abbrv="">measles</z:e>, and respiratory syncytial virus antigens, did not show any consistent or impressive changes </plain></SENT>
</text></document>